Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 23, 2015HaematologicaOpen Access

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

View Full Paper
Ask AI
Bookmark
Share

Authors

Srđan Verstovšek
Srđan VerstovšekUppsala UniversityRMRuben A. MesaUniversity of InsubriaJGJason GotlibOntario Institute for Cancer Research

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Verstovšek et al. (2015) studied this question.

synapsesocial.com/papers/6a7da9b2ac8a0219183c9507https://doi.org/10.3324/haematol.2014.115840
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>2013 · 1,764 citations
  2. 2Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies2011 · 56 citations
  3. 3Efficacy, Hematologic Effects, and Dose of Ruxolitinib in Myelofibrosis Patients with Low Starting Platelet Counts (50–100 × 109/L): A Comparison to Patients with Normal or High Starting Platelet Counts2012 · 14 citations
  4. 4Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial2013 · 191 citations
  5. 5A New Prognostic Scoring System for Primary Myelofibrosis Based on a Study of the International Working Group for Myelofibrosis Research and Treatment2008 · 109 citations